| 摘要 |
The invention relates to a mutated neublastin polypeptide comprising at least one glutaminic acid substitution of arginine at position 48,49 or 51. Such polypeptide exhibits prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin. |
